Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30

$0.61−0.06 (-8.25%)

Close on Nov 13, 2026Market cap $354.83KP/E –Yield –

Virax Biolabs ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$5.81M.

Period	Period end	Value	Change
FY2025	Mar 31, 2025	-$5.81M	–
FY2024	Mar 31, 2024	-$6.47M	–

Parsed from the XBRL in Virax Biolabs's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jun 26, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VRAX.

Operating margin-51515.2% · median -913114.9%

Net margin-40439.1% · median -871894.3%

Advertisement
300 × 250

See a number that looks wrong?